QPS Expands Laboratory Capabilities By Opening New, Cell-Based Assay Laboratory at Netherlands Facility

QPS Netherlands has expanded its cell-based assay capability in response to client demand for immunogenicity assessment for large molecule analysis, and for immune monitoring assays in drug development.

Having added neutralizing antibody assessments at its Netherlands facility, QPS now offers a complete package of immunogenicity testing on both sides of the Atlantic; this service is also available at QPS in Delaware.

The above research facilities both support the recently issued FDA Guidance on “Immunogenicity Assessment for Therapeutic Protein Products.” and the EMA Guideline on “Immunogenicity Assessment of Biotechnology-derived Therapeutic Proteins”

Investing in cell-based assay technology is another way QPS is providing robust and integrated ways for clients to perform immune monitoring during large molecule drug development.

20 years in pharma R&D navigation